1628-79-1

Usage

Uses

Used in Research and Chemical Synthesis:
1-(3,7-dinitro-10H-phenothiazin-10-yl)ethanone is used as a research compound for [application reason] in the field of chemical synthesis. Its unique structure and properties make it a valuable tool for exploring new chemical reactions and developing novel compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1-(3,7-dinitro-10H-phenothiazin-10-yl)ethanone is used as a starting material for the synthesis of various pharmaceutical compounds. Its potential reactivity and the presence of functional groups make it a promising candidate for the development of new drugs with specific therapeutic applications.
Used in Dye Industry:
1-(3,7-dinitro-10H-phenothiazin-10-yl)ethanone is used as an intermediate in the dye industry for [application reason]. Its yellow color and chemical properties make it suitable for the production of various dyes and pigments.
Used in Analytical Chemistry:
In analytical chemistry, 1-(3,7-dinitro-10H-phenothiazin-10-yl)ethanone is used as a reagent for [application reason]. Its unique chemical properties allow for specific interactions with other compounds, making it useful in the identification and quantification of various substances.

Upstream product

• 1747-90-6 3,11-dinitro-10H-phenothiazine 
• 108-24-7 acetic anhydride 
• 92-84-2 10H-phenothiazine 
• 1628-77-9 3-nitro-10H-phenothiazine 

Downstream Products

• 7506-02-7 10-acetyl-3,7-dinitro-10H-phenothiazine 5-oxide 
• 59436-28-1 10-acetyl-N,N'-dibenzylidene-10H-phenothiazine-3,7-diamine 
• 59436-29-2 10-acetyl-N,N'-bis-(2-hydroxy-benzylidene)-10H-phenothiazine-3,7-diamine 

Relevant academic research and scientific papers

Therapeutic use of diaminophenothiazines

The present invention relates generally to methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimised pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines, for instance compared to haematological effects.

PHENOTHIAZINE DIAMINIUM SALTS AND THEIR USE

The invention relates to compounds of general formula (I): wherein: each of R1 and R9 is independently selected from: -H, C1-4alkyl, C2-4alkenyl, and halogenated C1-4alkyl; each of R3NA and

METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS

This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesis and/or purification of certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as "diaminophenothiazinium compounds") including Methylthioninium Chloride (MTC) (also known as Methylene Blue). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment, prophylaxis, and diagnosis, etc., for example, a tauopathy; a disease of tau protein aggregation; Alzheimer's disease (AD); Pick's disease; Progressive Supranuclear Palsy (PSP); fronto temporal dementia (FTD); parkinsonism linked to chromosome 17 (FTDP-17); disinhibition-dementia-parkinsonism-amyotrophy complex (DDPAC); pallido-ponto-nigral degeneration (PPND); Guam-ALS syndrome; pallido-nigro-luysian degeneration (PNLD); cortico-basal degeneration (CBD); mild cognitive impairment (MCI); skin cancer; melanoma; methemoglobinemia; a viral infection; a bacterial infection; a protozoal infection; a parasitic infection; malaria; visceral leishmaniasis; African sleeping sickness; toxoplasmosis; giardiasis; Chagas' disease; Hepatitis C virus (HCV) infection; human immunodeficiency virus (HIV) infection; West Nile virus (WNV) infection; a synucleinopathy; Parkinson's disease (PD); dementia with Lewy bodies (DLB); multiple system atrophy (MSA); drug-induced parkinsonism; and pure autonomic failure (PAF).

3,7-DIAMINO-10H-PHENOTHIAZINE SALTS AND THEIR USE

This invention pertains generally to the field of phenothiazine compounds, and more particularly to certain stably reduced phenothiazine compounds, specifically, certain 3,7 diamino-10H-phenothiazine (DAPTZ) compounds of the following formula wherein: each of R1 and R9 is independently selected from: -H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: -H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R7NA and R7NB is independently selected from: -H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of HX1 and HX2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs (for example, methythioninium chloride, MTC).